Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor
Kevin Kalinsky(Emory University), Keith T. Flaherty(Massachusetts General Hospital), Peter J. O’Dwyer(University of Pennsylvania), Larry Rubinstein(National Cancer Institute), James A. Zwiebel(National Institutes of Health), David R. Patton(National Cancer Institute), Lisa M. McShane(National Cancer Institute), Carlos L. Arteaga(The University of Texas Southwestern Medical Center), Alice P. Chen(National Cancer Institute), Jasgit C. Sachdev(HonorHealth), Barbara A. Conley, Carolyn K. McCourt(Washington University in St. Louis), Fangxin Hong(Dana-Farber Cancer Institute), Robert J. Gray(Eastern Cooperative Oncology Group), Stanley R. Hamilton(Johns Hopkins Medicine), Edith P. Mitchell(Thomas Jefferson University Hospital), P. Mickey Williams(Frederick National Laboratory for Cancer Research), Shuli Li(Xijing Hospital), L. Austin Doyle(Ontario Institute for Cancer Research), Lyndsay N. Harris(University Hospitals Cleveland Medical Center)
Cited by 106
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.2k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k